Page 264 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Table 1. Demographics and baseline characteristics.
Characteristics
Comparative analysis
All zanubrutinib, N=1,550 Zanubrutinib, N=425a Ibrutinib, N=422b
Age in years, median (range) 67.0 (20-95) 68.0 (35-90) 68.0 (35-90)
<65, N (%) 600 (38.7) 160 (37.6) 148 (35.1)
≥65 to <75, N (%) 615 (39.7) 155 (36.5) 181 (42.9)
≥75, N (%) 335 (21.6) 110 (25.9) 93 (22.0)
Sex, N (%)
Male 1,027 (66.3) 280 (65.9) 295 (69.9)
Female 523 (33.7) 145 (34.1) 127 (30.1)
Race, N (%)
White 1,032 (66.6) 348 (81.9) 357 (84.6)
Asian 424 (27.4) 49 (11.5) 44 (10.4)
Other 51 (3.3) 11 (2.6) 4 (0.9)
Not reported or missing 43 (2.8) 17 (4.0) 17 (4.0)
Geographic region, N (%)c
Europe 551 (35.5) 259 (60.9) 250 (59.2)
Australia/New Zealand 414 (26.7) 60 (14.1) 60 (14.2)
Asia 406 (26.2) 45 (10.6) 43 (10.2)
North America 179 (11.5) 61 (14.4) 69 (16.4)
ECOG performance status, N (%)
0 692 (44.6) 174 (40.9) 164 (38.9)
1 763 (49.2) 239 (56.2) 238 (56.4)
2 95 (6.1) 12 (2.8) 20 (4.7)
Diagnosis, N (%)
CLL/SLL 938 (60.5) 324 (76.2) 324 (76.8)
Mantle cell lymphoma 140 (9.0) 0 0
Waldenström macroglobulinemia 249 (16.1) 101 (23.8) 98 (23.2)
Marginal zone lymphoma 93 (6.0) 0 0
Follicular lymphoma 59 (3.8) 0 0
Diffuse large B-cell lymphoma 45 (2.9) 0 0
Otherd 26 (1.7) 0 0
Prior treatment status, N (%)
Treatment naive 482 (31.1) 19 (4.5)e 18 (4.3)e
Relapsed/refractory 1,068 (68.9) 406 (95.5) 404 (95.7)
Prior lines of therapy, N (%)
0 482 (31.1) 19 (4.5)e 18 (4.3)e
1 496 (32.0) 237 (55.8) 231 (54.7)
2 275 (17.7) 99 (23.3) 86 (20.4)
≥3 297 (19.2) 70 (16.5) 87 (20.6)
Medical history, N (%)f
History of cardiac disordersg 368 (24.9) 117 (28.6) 116 (28.2)
History of atrial fibrillation and flutterh 101 (6.8) 29 (7.1) 26 (6.3)
History of hypertensionh 651 (44.1) 198 (48.4) 201 (48.9)
History of skin cancerh 20 (1.4) 1 (0.2) 2 (0.5)
Concomitant medications, N (%)i
Antithrombotic agentsj 413 (26.6) 126 (29.6) 138 (32.7)
CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; ECOG: Eastern Cooperative Oncology Group. aIncludes patients with Waldenström macroglobulinemia from ASPEN cohort 1 (N=101) and patients with CLL/SLL from ALPINE (N=324). bIncludes patients with Waldenström macroglobulinemia from ASPEN cohort 1 (N=98) and patients with CLL/SLL from ALPINE (N=324). cLocation of study site enroll- ment. Asia includes China (Mainland and Taiwan) and South Korea; Europe includes Austria, Belgium, Belarus, Bulgaria, Czech Republic, France, Germany, Greece, Italy, the Netherlands, the Russian Federation, Poland, Spain, Sweden, Turkey, and the UK; and North America includes the United States and Canada. dIncludes patients with Richter transformation (N=13), hairy cell leukemia (N=11), B-lineage lymphoma (N=1), and indo- lent lymphoma (N=1). ePatients with Waldenström macroglobulinemia from ASPEN cohort 1. fPercentages are expressed using the number of pa- tients with available medical history (all zanubrutinib, N=1,477; ASPEN/ALPINE zanubrutinib, N=409; ASPEN/ALPINE ibrutinib, N=411). gSystem organ class. hIndividual preferred term. iConcomitant medications are defined as medications that started before the first dose of study treatment and were continuing at the time of the first dose of study treatment or started on or after the date of the first dose of zanubrutinib treatment up to the last zanubrutinib dose date + 30 days or initiation of a new anticancer therapy. Patients with >1 medication within a class level and preferred name were counted only once within that class level and preferred name. Medication class was designated per the Anatomical Therapeutic Chem- ical classification system. jExcluding acetylsalicylic acid.
Haematologica | 109 July 2024
2278